AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Albaad Massuot Yitzhak Ltd.

Investor Presentation Mar 12, 2024

6630_rns_2024-03-12_9fb02ba4-3ed4-4599-90d9-17aade1f53b6.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

March 2024

Financial Results Overview 2023

1

FORWARD LOOKING STATEMENT

Legal disclaimer Important notice

This presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any shares of Albaad Massuot Yitzhak LTD. (the "Company") or any of its affiliated entities.

This presentation contains partial information from the public reports of the Company under the Israeli Securities Law 5728-1968 (the "Securities Law"), which can be accessed on the Israeli Securities Authority's website, www.magna.isa.gov.il. A review of this presentation is not a substitute for a review of the detailed reports of the Company under the Securities Law and is not meant to replace or qualify them; rather, the presentation is prepared merely for the convenience of the reader, with the understanding that the detailed reports are being reviewed simultaneously.

Everything stated in this Presentation with respect to an analysis of the Company's business is merely a summary and any forwardlooking statements involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements and are based on current expectations, estimations, and assumptions, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this presentation due to a variety of factors, many of which are beyond the Company's control, including, without limitation, certain risk factors contained in the Company's reports. The Company disclaims any obligation or commitment to update these forward-looking statements to reflect new information, future events or developments or changes in expectations, estimates, projections and assumptions or otherwise.

ALBAAD'S 2023 FINANCIAL TURNAROUND

Albaad faced the challenge of achieving financial stability within the banking system with this as our primary objective, we not only met but exceeded our goals

By Q3.2023, we had demonstrated covenant compliance without the need for waivers

a significant achievement that was originally planned for later in 2024 year. by Q4.2023, we achieved further improvement

Cash flow was exceptionally strong, reaching a peak of 233m NIS from operating activity

This enables the company to fund its ongoing investment plan, including:

  • An investment in Dimona of 86m NIS
  • A second payment of 32m NIS for the acquisition of Optimal Care
  • A reduction of gross debt by 56m NIS & net debt by 48m NIS

YEAR 2023 COMPANY MAIN HIGHLIGHTS CONCLUDING 2023 WITH

  • SALES INCREASE OF 18% TO 1.7B NIS
  • GROSS PROFIT MARGIN improved to 20%
  • EBIT* INCREASE OF 83M NIS TO 94M NIS
  • EBITDA** INCREASE OF 85M NIS TO 182M NIS
  • NET PROFIT** INCREASE OF 76M NIS TO 41M NIS
  • OPERATING Cash Flow 233M NIS
  • NET DEBT DECREASE OF 48M NIS

* EBIT before others ** EBITDA & Net profit from continued operation

SALES & EBITDA* TRENDS 2021-2023

QUARTERLY BASIS (000 NIS)

NET DEBT TO EBITDA* TRENDS 2021-2023

QUARTERLY BASIS (000 NIS)

HIGHLIGHTS

Year 2023 Results VS. Last year (000 NIS)

Year
23
Year
22
Var Var
%
Sales
+18%
Sales in original currency +6%
Sales 1
710
479
,
,
1
453
877
,
,
256
602
,
17
6%
EBIT 93
038
,
(11
228)
,
104
266
,
+83M
Operating Profit
+104 M including others
EBIT
(Before
Others)
94
510
,
11
853
,
82
657
,
697
4%
EBITDA
(Continued
operation)
182
461
,
97
296
,
85
165
,
87
5%
+88% EBITDA EBITDA 182
270
,
1
292
,
180
979
,
+85 M continued operation
+181 M inc. discontinued operation
Net
Profit
(Continued
operation)
41
219
,
(35
123)
,
76
342
,
+175M
Net Profit
Profit
Net
31
001
,
(143
956)
,
174
957
,
From negative to positive CF
Operating
activities
-
233
229
,
18
568
,
214
661
,

SALES & EBIT* BY DIVISION

Year 2023 VS. Last year (000 NIS)

Sales EBIT
Year
23
Year
22
Var
%
(Org
)
Var
%
Year
23
Year
22
Albaad
Europe
from
%
sales
572
1
300
,
,
1
079
479
,
,
20
5%
6
8%
63
043
,
4
8%
31
839
,
2
9%
Albaad
IL
%
from
sales
222
139
,
213
344
,
1%
4
(0
5%)
(3
827)
,
(1
7%)
(303)
(0
1%)
Albaad
Fabric
IL
from
%
sales
363
996
,
364
094
,
(0
0%)
(11
1%)
33
176
,
9
1%
4
344
,
1
2%
Albaad
Fem
IL
from
sales
%
250
542
,
207
509
,
7%
20
0%
10
37
080
,
14
8%
(5
496)
,
(2
6%)
Intercompany (426
770)
,
(410
549)
,
(9
235)
,
1
839
,
HeadQuarter
&
Others
(25
727)
,
(20
370)
,
Total
Company
%
from
sales
1
710
479
,
,
453
1
877
,
,
6%
17
9%
5
510
94
,
5
5%
853
11
,
0
8%
Other
Income/Expenses
(1
472)
,
(23
081)
,
Company
Total
from
sales
%
1
710
479
,
,
1
453
877
,
,
17
6%
5
9%
93
038
,
4%
5
(11
228)
,
(0
8%)

HIGHLIGHTS

Q4.2023 Results VS. Last year (000 NIS)

Q4
2023
Q4
2022
Var Var
%
+15% Sales
Sales in original currency +1.5%
Sales 418
909
,
364
716
,
54
193
,
14
9%
EBIT 24
872
,
(23
899)
,
48
771
,
+34M Operating Profit EBIT
(Before
Others)
25
628
,
(8
349)
,
33
977
,
+49 M including others EBITDA
(Continued
operation)
48
370
,
13
108
,
35
262
,
269
0%
+269% EBITDA
+35 M continued operation
+62 M inc. discontinued operation
EBITDA 53
132
,
(9
092)
,
62
224
,
Net
Profit
(Continued
operation)
12
216
,
(29
407)
,
41
623
,
+71M Net Profit
From negative to positive
Net
Profit
12
497
,
(58
551)
,
71
048
,
CF
Operating
activities
-
53
757
,
15
734
,
38
023
,
241
7%

SALES & EBIT* BY DIVISION

Q4.2023 VS. Last year (000 NIS)

Sales EBIT
Q4
2023
Q4
2022
Var
%
(Org
)
Var
%
Q4
2023
Q4
2022
Albaad
Europe
from
sales
%
331
164
,
275
246
,
20
3%
4
4%
23
125
,
7
0%
776
0
3%
Albaad
IL
%
from
sales
44
976
,
41
209
,
1%
9
3%
4
(4
631)
,
(10
3%)
(8
258)
,
(20
0%)
Fabric
Albaad
IL
from
sales
%
92
887
,
91
595
,
1
4%
(11
9%)
8
990
,
9
7%
3
209
,
3
5%
Albaad
Fem
IL
%
from
sales
56
665
,
57
988
,
(2
3%)
(11
5%)
7
077
,
12
5%
1
920
,
3
3%
Intercompany (106
783)
,
(101
322)
,
(1
199)
,
(608)
HeadQuarter
&
Others
(7
734)
,
(5
388)
,
Total
Company
%
from
sales
418
909
,
364
716
,
9%
14
5%
1
25
628
,
6
1%
(8
349)
,
(2
3%)
Other
Income/Expenses
(756) (15
550)
,
Company
Total
%
from
sales
418
909
,
364
716
,
14
9%
1
5%
24
872
,
5
9%
(23
899)
,
(6
6%)

*

BALANCE SHEET

AS OF 31.12.2023 VS. 31.12.2022 (000 NIS)

31
12
2023
from
total
%
31
12
2022
from
total
%
Cash
and
cash
equivalents
19
133
,
1% 27
186
,
2%
19M Cash on hand Trade
Receivables
213
956
,
14% 254
547
,
16%
Inventory 328
969
,
21% 393
313
,
25%
Other
Current
Assets
32
184
,
2% 37
580
,
2%
64M Reduction of inventory Current
Total
Assets
594
242
,
38% 712
626
,
45%
84M reduction exc. currency impact Current
Non
Assets
988
361
,
62% 883
964
,
55%
Total
Assets
1
582
603
,
,
100% 1
596
590
,
,
100%
403M Equity Credit
banking
&
institutions
392
243
,
25% 538
805
,
34%
Trade
Payables
222
718
,
14% 252
518
,
16%
Current
Total
Liabilities
713
183
,
45% 910
734
,
57%
25%
Equity from total
balance sheet
Total
Long-Term
Liabilities
466
178
,
29% 331
194
,
21%
Equity 403
242
,
25% 354
662
,
22%
Total
liabilities
1
582
603
,
,
100% 1
596
590
,
,
100%

INNOVATION & FUTURE GROWTH Green product line in Dimona - the next generation

  • o Green hybrid production line that enables production in both paper technology and green non-woven technology
  • o The Hydrofine® Products from the new hybrid line will serve both flushable MTT wipes as well as traditional baby, cosmetic and cleaning wipes
  • o All Hydrofine® Products are made from 100% natural, plant based components
  • o Production is expected during H2 2024
  • o Approximately 146 MNIS invested up to December 2023 from total budget of about 200 MNIS

SUMMARY

Meeting & Improving Banks Initial Covenants*

o Net Liabilities to EBITDA Ratio 2.11 / Tangible Equity Ratio 26.5%

Maintaining positive performance for EBITDA Growth & Operating Cash Flow

  • o Inventory reduction of 64m NIS since Dec 2022
  • o Annual Operating Cash Flow of 233m NIS
  • o Annual Free Cash Flow** of 124m NIS including Dimona line 2 investments

* Banks covenants are excluding intangible assets ** FCF 124 m = Operating CF 233 m + Leasing liability repayment (-30 m) Interest (-34 m) + CAPEX (-114 m)

DIVERSE PRODUCT RANGE

Home Care

Wipes Disinfecting /All Purpose Cleaning / Windows / Floors / Furnitures / Automotive

Hygiene

Wipes Moist Toilet Paper Consumer Healthcare Adult Care

Baby Care

Wipes Based formulas: Aqua / Gel / Rich Lotion / Diaper Rash Cream / Bathing Wipes

Wipes

Cosmetics

Makeup Remover / Hydrating / Exfoliating (abrasive) / Anti-aging

Fem. Care Tampons, Wipes Tampons: Tampon with a plastic applicator Tampon without applicator Tampon with a paper applicator Intimate Wipes

ALBAAD's ADDED VALUE

Global deployment

  • ✓ Avoid Supply chain disruption
  • ✓ Back up plan in case of disruption in one of our facilities
  • ✓ Sufficient capacity in case market needs fast growing
  • ✓ Nonwoven Production Albaad produces majority of its own nonwoven consumption

Marketing

  • ✓ Identify and adjust the needs of each customer
  • ✓ Highly qualified team well experienced with A brands needs
  • ✓ Well informed on innovative raw materials (fabrics, laminate, Chemicals), products and customers trends worldwide

R&D

  • ✓ Well trained and highly educated R&D corporate's team – led by PhD.
  • ✓ Focuses on innovation
  • ✓ Expertise in all production chain – Fibers, Fabrics and End-Products

FURTHER STRENGTHENING & FUTURE GROWTH

Further Strengthening

  • o Continue to improve Net Debt to EBITDA
  • o Closing Sale & Lease Back transaction of Dimona facility
  • o Proceed with Tampons division Deal

Future Growth

  • o Dimona Green hybrid production line as milestone for growth in our sustainability strategy
  • o Inhouse development of Spunlace based tampon potential for new market
  • o Focusing on new profitable customers & Innovation products expanding Europe sales teams
  • o Innovation as state of mind in products, production & processes

THANK YOU

17

Talk to a Data Expert

Have a question? We'll get back to you promptly.